Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 2/2017

01-04-2017 | Review Article

The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities

Authors: Nicole J. Flynn, Rajasekharan Somasundaram, Kimberly M. Arnold, Jennifer Sims-Mourtada

Published in: Targeted Oncology | Issue 2/2017

Login to get access

Abstract

The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a variety of solid tumors, including breast, ovarian, prostate, melanoma, and colorectal cancer. The function of B cells in solid tumors is controversial, with many studies reporting a pro-tumor effect, while other studies demonstrate a role for B cells in the anti-tumor immune response. In this review, we discuss the prognostic ability of B cells in solid tumors as well as the mechanisms by which B cells can either promote or suppress anti-tumor immunity. Additionally, we review current therapeutic strategies that may target both pro- and anti-tumor B cells.
Literature
1.
Naito Y et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491–4.PubMed
2.
Hu WH et al. Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. J Surg Oncol. 2015;112(4):421–6.PubMedCrossRef
3.
Liu S et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):R48.PubMedPubMedCentralCrossRef
4.
Kawai O et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113(6):1387–95.PubMedCrossRef
5.
Fukunaga A et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28(1):e26–31.PubMedCrossRef
6.
Oshikiri T et al. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol. 2003;84(4):224–8.PubMedCrossRef
7.
Davidsson S et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2012;26(3):448–55.PubMedCrossRef
8.
9.
Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des. 2009;15(16):1879–92.PubMedCrossRef
10.
Menetrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 2009;69(20):7895–8.PubMedCrossRef
11.
Erdag G et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070–80.PubMedPubMedCentralCrossRef
12.
Punt CJ et al. Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother. 1994;38(4):225–32.PubMedCrossRef
13.
Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977–82.PubMedCrossRef
14.
Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol. 2013;131(4):959–71.PubMedCrossRef
15.
Viau M, Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol. 2005;114(1):17–26.PubMedCrossRef
16.
Liang Y et al. Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells. Clin Immunol. 2011;138(1):33–40.PubMedCrossRef
17.
18.
Garraud O et al. Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol. 2012;13:63.PubMedPubMedCentralCrossRef
19.
20.
Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27(10):521–30.PubMedCrossRef
21.
Wang WW et al. CD19 + CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. Oncotarget. 2015;6(32):33486–99.PubMedPubMedCentral
22.
23.
Zhou X et al. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells. Oral Oncol. 2016;53:27–35.PubMedCrossRef
24.
25.
Mohammed ZM et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013;109(6):1676–84.PubMedPubMedCentralCrossRef
26.
Wei X et al. Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol. 2016;37(5):6581–8.PubMedCrossRef
27.
Blair PA et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010;32(1):129–40.PubMedCrossRef
28.
Moir S et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8):1797–805.PubMedPubMedCentralCrossRef
29.
Kardava L et al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest. 2011;121(7):2614–24.PubMedPubMedCentralCrossRef
30.
Titanji K et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest. 2010;120(11):3878–90.PubMedPubMedCentralCrossRef
31.
Saadoun D et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren’s syndrome-associated lymphoproliferation. Arthritis Rheum. 2013;65(4):1085–96.PubMedPubMedCentralCrossRef
32.
Martinez-Rodriguez M, Thompson AK, Monteagudo C. A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma. Histopathology. 2014;65(5):726–8.PubMedCrossRef
33.
Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59(9):972–7.PubMedPubMedCentralCrossRef
34.
35.
Thompson E et al. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29(3):249–58.PubMedCrossRef
36.
37.
Del Mar Valenzuela-Membrives M et al. Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer. Oncotarget. 2016;7(44):71608–19.PubMedPubMedCentral
38.
39.
Liao Y et al. Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. Med Oncol. 2013;30(4):727.
40.
41.
42.
43.
Fortes C et al. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Res. 2015;25(4):306–11.PubMedCrossRef
44.
Tougeron D et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009;22(9):1186–95.PubMedCrossRef
45.
Brown JR et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20(23):5995–6005.PubMedPubMedCentralCrossRef
46.
Mahmoud SM et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132(2):545–53.PubMedCrossRef
47.
Schmidt M et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012;18(9):2695–703.PubMedCrossRef
48.
Schmidt M et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405–13.PubMedCrossRef
49.
Fan C et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 2011;4:3.PubMedPubMedCentralCrossRef
50.
51.
Iglesia MD et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 2014;20(14):3818–29.PubMedPubMedCentralCrossRef
52.
53.
Hanker LC et al. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res Treat. 2013;137(2):407–16.PubMedCrossRef
54.
Ladanyi A et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother. 2011;60(12):1729–38.PubMedCrossRef
55.
Garg K et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol. 2016;54:157–64.PubMedCrossRef
56.
Lardone RD et al. Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma. Oncotarget. 2016;7(12):14415–28.PubMedPubMedCentral
57.
Al-Shibli KI et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220–7.PubMedCrossRef
58.
Fujimoto M et al. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. Hum Pathol. 2013;44(8):1569–76.PubMedCrossRef
59.
Lohr M et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013;333(2):222–8.PubMedCrossRef
60.
Al-Shibli K et al. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS. 2010;118(5):371–82.PubMedCrossRef
61.
Santoiemma PP et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol. 2016;143(1):120–7.PubMedCrossRef
62.
Nielsen JS et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281–92.PubMedCrossRef
63.
Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016;22(12):3005–15.PubMedCrossRef
64.
Shimabukuro-Vornhagen A et al. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget. 2014;5(13):4651–64.PubMedPubMedCentralCrossRef
65.
Berntsson J et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer. 2016;139(5):1129–39.PubMedCrossRef
66.
Meshcheryakova A et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One. 2014;9(6):e99008.PubMedPubMedCentralCrossRef
67.
Parkes H et al. In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. Br J Cancer. 1988;58(6):715–22.PubMedPubMedCentralCrossRef
68.
Smorodin EP, Sergeyev BL. The level of IgG antibodies reactive to TF, Tn and alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival. Exp Oncol. 2016;38(2):117–21.PubMed
69.
Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer (review). Oncol Rep. 1998;5(3):753–61.PubMed
70.
Pectasides D et al. Clinical value of CA 15–3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol. 1996;19(5):459–64.PubMedCrossRef
71.
Kulic A et al. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients. Med Oncol. 2009;27(3):887–93.PubMedCrossRef
72.
von Mensdorff-Pouilly S et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18(3):574–83.CrossRef
73.
Bosisio FM et al. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol. 2016;29(4):347–58.PubMedCrossRef
74.
Karagiannis P et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. Oncoimmunology. 2015;4(11):e1032492.PubMedPubMedCentralCrossRef
75.
Hillen F et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother. 2008;57(1):97–106.PubMedCrossRef
76.
Kurebayashi Y et al. Comprehensive immune profiling of lung adenocarcinomas reveals four immunosubtypes with plasma cell subtype a negative indicator. Cancer Immunol Res. 2016;4(3):234–47.PubMedCrossRef
77.
Dong HP et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006;125(3):451–8.PubMedCrossRef
78.
79.
Song IH, et al. Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer. Cancer Res Treat. 2016. doi:10.​4143/​crt.​2016.​215.
80.
Montfort A, et al. A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res. 2016;23(1):250–62.
81.
Goc J et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74(3):705–15.PubMedCrossRef
82.
Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol. 2015;6:67.PubMedPubMedCentralCrossRef
83.
Cipponi A et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012;72(16):3997–4007.PubMedCrossRef
84.
de Chaisemartin L et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011;71(20):6391–9.PubMedCrossRef
85.
Sautes-Fridman C et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407.PubMedPubMedCentralCrossRef
86.
Imahayashi S et al. Tumor-infiltrating B-cell-derived IgG recognizes tumor components in human lung cancer. Cancer Investig. 2000;18(6):530–6.CrossRef
87.
Yasuda M et al. Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer Res. 2002;62(6):1751–6.PubMed
88.
Mizukami M et al. Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth. Anticancer Res. 2006;26(3A):1827–31.PubMed
89.
Campa MJ et al. Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. Cancer Immunol Immunother. 2016;65(2):171–80.PubMedCrossRef
90.
Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 2003;63(12):3275–80.PubMed
91.
Hansen MH, Ostenstad B, Sioud M. Antigen-specific IgG antibodies in stage IV long-time survival breast cancer patients. Mol Med. 2001;7(4):230–9.PubMedPubMedCentral
92.
Coronella JA et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002;169(4):1829–36.PubMedCrossRef
93.
Pavoni E et al. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol. 2007;7:70.PubMedPubMedCentralCrossRef
94.
Fremd C et al. Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. Oncoimmunology. 2016;5(1):e1057387.PubMedCrossRef
95.
Wang Y et al. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. Breast Cancer Res Treat. 2007;104(2):129–44.PubMedCrossRef
96.
Kotlan B et al. Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. Immunol Lett. 1999;65(3):143–51.PubMedCrossRef
97.
Coronella JA et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61(21):7889–99.PubMed
98.
Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A. 2001;98(22):12659–64.PubMedPubMedCentralCrossRef
99.
Pedersen AE et al. Wildtype p53-specific antibody and T-cell responses in cancer patients. J Immunother. 2011;34(9):629–40.PubMedCrossRef
100.
Maehara Y et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer. 1999;85(2):302–8.PubMedCrossRef
101.
Shiota G et al. Clinical significance of serum P53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol. 1998;99(1):41–51.PubMed
102.
Goodell V et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol. 2006;24(5):762–8.PubMedCrossRef
103.
104.
Peyrat JP et al. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 1995;345(8950):621–2.PubMedCrossRef
105.
106.
107.
Varga EM et al. Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2013;131(5):1419–21.PubMedCrossRef
108.
Chen LF et al. Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis. Mediat Inflamm. 2014;2014:635293.
109.
Lin W et al. B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjogren’s syndrome: the similarities and differences. Arthritis Res Ther. 2014;16(3):R118.PubMedPubMedCentralCrossRef
110.
Karagiannis P et al. IgG4 antibodies and cancer-associated inflammation: insights into a novel mechanism of immune escape. Oncoimmunology. 2014;2(7):e24889.CrossRef
111.
112.
Raina A et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med. 2008;132(1):48–53.PubMed
113.
Harshyne LA et al. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol. 2015;18(2):206–15.PubMedPubMedCentralCrossRef
114.
115.
Kimura Y, Harada K, Nakanuma Y. Pathologic significance of immunoglobulin G4-positive plasma cells in extrahepatic cholangiocarcinoma. Hum Pathol. 2012;43(12):2149–56.PubMedCrossRef
116.
Tan J et al. Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer. Oncol Rep. 2015;33(3):1512–8.PubMed
117.
Fragoulis GE, Moutsopoulos HM. IgG4 syndrome: old disease, new perspective. J Rheumatol. 2010;37(7):1369–70.PubMedCrossRef
118.
Yanaba K et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639–50.PubMedCrossRef
119.
120.
Flores-Borja F et al. CD19 + CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5(173):173ra23.PubMedCrossRef
121.
Carter NA et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011;186(10):5569–79.PubMedCrossRef
122.
Zhang Y et al. Mammary-tumor-educated B cells acquire LAP/TGF-beta and PD-L1 expression and suppress anti-tumor immune responses. Int Immunol. 2016;28(9):423–33.PubMedCrossRef
123.
Zhang Y et al. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 2013;62(1):87–99.PubMedCrossRef
124.
Iwata Y et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530–41.PubMedPubMedCentralCrossRef
125.
Kessel A et al. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2012;11(9):670–7.PubMedCrossRef
126.
Tian J et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol. 2001;167(2):1081–9.PubMedCrossRef
127.
Parekh VV et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol. 2003;170(12):5897–911.PubMedCrossRef
128.
Tadmor T et al. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol Immunother. 2011;60(5):609–19.PubMedCrossRef
129.
Olkhanud PB et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71(10):3505–15.PubMedPubMedCentralCrossRef
130.
Olkhanud PB et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009;69(14):5996–6004.PubMedPubMedCentralCrossRef
131.
132.
Bodogai M et al. Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells. Cancer Res. 2015;75(17):3456–65.PubMedPubMedCentralCrossRef
133.
Shao Y et al. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway. Cancer Lett. 2014;355(2):264–72.PubMedCrossRef
134.
135.
de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7(5):411–23.PubMedCrossRef
136.
Meyer S et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One. 2012;7(6):e38222.PubMedPubMedCentralCrossRef
137.
Staquicini FI et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008;68(20):8419–28.PubMedPubMedCentralCrossRef
138.
139.
Xander P et al. Crosstalk between B16 melanoma cells and B-1 lymphocytes induces global changes in tumor cell gene expression. Immunobiology. 2013;218(10):1293–303.PubMedCrossRef
140.
Perez EC et al. B-1 lymphocytes increase metastatic behavior of melanoma cells through the extracellular signal-regulated kinase pathway. Cancer Sci. 2008;99(5):920–8.PubMedCrossRef
141.
Choi J et al. Differential expression of immune-related markers in breast cancer by molecular phenotypes. Breast Cancer Res Treat. 2012;137(2):417–29.PubMedCrossRef
142.
Rosser EC et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med. 2014;20(11):1334–9.PubMedCrossRef
143.
144.
Matsumoto M et al. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity. 2011;34(5):703–14.PubMedCrossRef
145.
Bansal SC et al. Ex vivo removal of serum IgG in a patient with colon carcinoma: some biochemical, immunological and histological observations. Cancer. 1978;42(1):1–18.PubMedCrossRef
146.
Barbera-Guillem E et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother. 2000;48(10):541–9.PubMedCrossRef
147.
Kim S et al. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother. 2008;31(5):446–57.PubMedCrossRef
148.
Brodt P, Gordon J. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol. 1978;121(1):359–62.PubMed
149.
Monach PA, Schreiber H, Rowley DA. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation. 1993;55(6):1356–61.PubMedCrossRef
150.
Qin Z et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4(5):627–30.PubMedCrossRef
151.
Manning TC et al. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(−/−) mice. J Immunol. 1997;159(10):4665–75.PubMed
152.
Aklilu M et al. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004;15(7):1109–14.PubMedCrossRef
153.
154.
Peuvrel L et al. Melanoma and rituximab: an incidental association? Dermatology. 2013;226(3):274–8.PubMedCrossRef
155.
Diehl L et al. The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med (Berl). 2000;78(7):363–71.CrossRef
156.
Gladue RP et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 2011;60(7):1009–17.PubMedCrossRef
157.
Hunter TB et al. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol. 2007;65(5):479–86.PubMedCrossRef
158.
Carpenter EL et al. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009;7:93.PubMedPubMedCentralCrossRef
159.
Ruter J et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10(10):983–93.PubMedPubMedCentralCrossRef
160.
161.
162.
Guan H et al. PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in invasive breast cancer. Oncoimmunology. 2016;5(2):e1075112.PubMedCrossRef
163.
Colluru VT et al. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2013;34(4):193–204.PubMedCrossRef
164.
165.
Colluru VT, McNeel DG. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. 2016;7(42):67901–18.
166.
Wennhold K, et al. CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget. 2016.
167.
Shin CA, et al. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Oncotarget. 2016;7(29):46173–86.
Metadata
Title
The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities
Authors
Nicole J. Flynn
Rajasekharan Somasundaram
Kimberly M. Arnold
Jennifer Sims-Mourtada
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 2/2017
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-017-0481-x

Other articles of this Issue 2/2017

Targeted Oncology 2/2017 Go to the issue

Leading Article

Immuno-Oncology: The Third Paradigm in Early Drug Development

Adis Drug Evaluation

Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma

Review Article

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Review Article

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

Original Research Article

Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy

Short Communication

Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits